US Patent Issued to Astellas Pharma on Oct. 27 for "Multispecific antibody binding to ActRIIA, ActRIIB, and Fn14" (Japanese Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,774,338, issued on Oct. 27, was assigned to Astellas Pharma Inc. (Tokyo).

"Multispecific antibody binding to ActRIIA, ActRIIB, and Fn14" was invented by Shinji Soga (Tokyo), Takeshi Shigenaga (Tokyo) and Takeshi Tsutsumi (Tokyo).

According to the abstract* released by the U.S. Patent & Trademark Office: "[Problem] Provided is a multispecific antibody for preventing or treating amyotrophic diseases such as inclusion body myositis by binding to ActRIIA, ActRIIB, and Fn14, and inhibiting an amyotrophic action which occurs via ActRIIA, ActRIIB, and Fn14.[Means for Solution] The present inventors have conducted studies on a multispecific antibody, and provided a multispecific antibody inc...